Jame Abraham, MD, FACP (@jamecancerdoc) ranks #25 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 5 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: SERENA-4, VERITAC-2 (vepdegestrant). CMS Open Payments lists no 2025 general payments.
At a Glance
- 2 posts naming a trial in 2026
- 2 trials discussed by name
- Breast Cancer: US #25 · 5 physicians engaged
- CMS Open Payments lists no 2025 general payments.
This Month
What Jame Abraham, MD, FACP has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Jame Abraham, MD, FACP
Physicians who reposted Jame Abraham, MD, FACP’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #25 | — | 5 | 5 | Full ranking |
Trials Jame Abraham, MD, FACP Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| SERENA-4 | 1 | #8 of 8 | Sep 12, 2026 |
| VERITAC-2 (vepdegestrant) | 1 | #9 of 18 | May 1, 2026 |
Jame Abraham, MD, FACP on SERENA-4
SERENA-4 trial did not meet primary objective of statistically significant improvement in progression-free survival, however a numerical improvement was observed https://t.co/fzNuYclSVX https://t.co/16kvrp7TQZ
Jame Abraham, MD, FACP on VERITAC-2 (vepdegestrant)
FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer https://t.co/KNKqZ13Soi
Jame Abraham, MD, FACP’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer @FDAOncology @FDA @OncoAlert https://t.co/3pDOYWrHWY https://t.co/a7sqyRbjk5
Absolutely practice changing!! One of the most stunning developments in the treatment of patients with metastatic pancreatic cancer !! It is one of the rare moments in oncology which you will always remember ! Like the imatinib, trastuzumab presentations @ASCO #ASCO26 @OncoAlert https://t.co/GGhJ8UxizT
Congratulations @AgrimaMianMD @ClevelandClinic @ccfhemonc @IMG_Oncologists recipient of @ConquerCancerFd Young Investigator Award !! So proud of you !! @ASCO #asco2026 https://t.co/GhyfmdBal1
Great to catch up with the @TataMemorial team @cspramesh at @ASCO @ConquerCancerFd meeting ! #ASCO2026 ! https://t.co/7fLT4Jb1Re
Dates, timings and locations of some of the key breast cancer presentations at @ASCO #ASCO2026 @OncoAlert https://t.co/XYQ4y59tYO
Industry Payments
CMS Open Payments · 2025 general payments
$0 across 0 payments